Payment overview · 2025
General Payments
$348.76
15 reported records · 9 companies
Healthcare provider profile · identity verified
Ralph Bruce Geiger, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SEBASTIAN, FL · NPI 1245294073
Verified facts
What the public records show
CMS Open Payments records show Ralph Bruce Geiger, M.D. received $348.76 in general payments during 2025 across 15 reported records.
Phathom Pharmaceuticals, Inc. accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.33 | 27.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $72.95 | 20.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.08 | 13.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.79 | 10.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.40 | 9.0% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $19.24 | 5.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.23 | 5.2% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $15.72 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.02 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $348.76 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $94.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.08 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $36.79 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.79 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 121 |
| Losartan Potassium | Losartan Potassium | 403 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 107 |
| Tramadol Hcl | Tramadol Hcl | 343 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 330 | 95 |
| Alprazolam | Alprazolam | 328 | 81 |
| Montelukast Sodium | Montelukast Sodium | 315 | 103 |
| Lisinopril | Lisinopril | 308 | 92 |
| Omeprazole | Omeprazole | 284 | 81 |
| Meloxicam | Meloxicam | 268 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 73 |
| Metformin Hcl | Metformin Hcl | 248 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 71 |
| Gabapentin | Gabapentin | 236 | 69 |
| Simvastatin | Simvastatin | 236 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 218 | 55 |
| Trazodone Hcl | Trazodone Hcl | 199 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 34 |
| Potassium Chloride | Potassium Chloride | 138 | 50 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 135 | 43 |
| Eliquis | Apixaban | 134 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 46 |
| Pioglitazone Hcl | Pioglitazone Hcl | 119 | 32 |
| Furosemide | Furosemide | 118 | 39 |
| Allopurinol | Allopurinol | 113 | 35 |
| Ozempic | Semaglutide | 95 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 31 |
| Atenolol | Atenolol | 91 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 28 |
| Lorazepam | Lorazepam | 90 | 21 |
| Famotidine | Famotidine | 86 | 30 |
| Glimepiride | Glimepiride | 85 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 34 |
| Mupirocin | Mupirocin | 75 | 41 |
| Ezetimibe | Ezetimibe | 70 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 18 |
| Metformin Hcl Er | Metformin Hcl | 61 | 16 |
| Clonazepam | Clonazepam | 57 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 32 |
| Bupropion Xl | Bupropion Hcl | 55 | 19 |
| Carvedilol | Carvedilol | 53 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 46 |
| Diazepam | Diazepam | 53 | 14 |
| Lovastatin | Lovastatin | 53 | 15 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Donepezil Hcl | Donepezil Hcl | 51 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Meclizine Hcl | Meclizine Hcl | 51 | 22 |
| Buspirone Hcl | Buspirone Hcl | 50 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Clonidine Hcl | Clonidine Hcl | 46 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 38 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Finasteride | Finasteride | 44 | 14 |
| Terazosin Hcl | Terazosin Hcl | 44 | 11 |
| Ibuprofen | Ibuprofen | 43 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 11 |
| Sertraline Hcl | Sertraline Hcl | 39 | 13 |
| Warfarin Sodium | Warfarin Sodium | 38 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | 15 |
| Spironolactone | Spironolactone | 36 | 11 |
| Clonidine | Clonidine | 35 | suppressed |
| Prednisone | Prednisone | 35 | 16 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 22 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 14 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $348.76 · 15 records | Phathom Pharmaceuticals, Inc. | Cologuard Collection Kit, LYMPHA PRESS OPTIMAL PLUS(US) BT, MOUNJARO, Ozempic, PCD-51 731A (US) - White, PCD-52 737A (US) White, SYNTHROID, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, Wegovy, Xhance, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error